12:00 AM
Dec 23, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

AirFluSal Forspiro salmeterol/fluticasone regulatory update

Novartis' Sandoz generic pharmaceuticals division said Denmark approved AirFluSal Forspiro salmeterol/fluticasone to treat patients with asthma and/or chronic obstructive pulmonary disease (COPD). The approval follows completion...

Read the full 108 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >